when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

KEYTRUDA · news · pharmadog

← back to KEYTRUDA

News mentioning KEYTRUDA

99 stories

29dBiopharma layoffs must double in H2 for 2026 to match 2025 cutsbiospace

29dSummit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 16, 26Merck wins first approval of a PCSK9 cholesterol pillbiopharma dive

Jul 15, 26Merck ADC, in China study, shows potential to replace chemo in lung cancerbiopharma dive

Jul 15, 26STAT+: Celcuity’s breast cancer drug approved, its firststat

Jul 15, 26Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytrudabiospace

Jul 14, 26STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last yearstat

Jul 13, 26Agenus surges on study pivot; Apnimed lines up an IPObiopharma dive

Jul 2, 26Roche KRAS drug succeeds in head-to-head lung cancer studybiopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 15, 26Medicare drug price rule may target under-the-skin Keytruda and Opdivobiopharma dive

Jun 12, 26Merck brings Welireg-Keytruda combo to treat kidney cancerendpoints

Jun 11, 26Summit pulls $500M share sale a day after announcing itbiopharma dive

Jun 9, 26Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesbiopharma dive

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

Jun 2, 26What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitendpoints

May 31, 26Akeso, Summit drug extends survival in closely watched lung cancer trialbiopharma dive

May 29, 26At ASCO, Merck makes case for a ‘cornerstone’ cancer drugbiopharma dive

May 18, 26Merck ADC, licensed from China, hits mark in first big global trialbiopharma dive

May 18, 26Regeneron immunotherapy combo comes up short in melanoma trialbiopharma dive

May 15, 26Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBConclive

May 14, 26Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Canceronclive

May 13, 26Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapyonclive

May 12, 26Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Canceronclive

May 12, 26Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bondonclive

May 12, 26Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanomaonclive

May 12, 26Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanomaonclive

May 12, 26Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Riskonclive

May 12, 26GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive

← prevpage 2 of 4next →